Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Two-center, Double-blind, Randomized, Placebo-controlled Multi-period Crossover (N-of-1) Study to Evaluable the Feasibility, Safety, and Efficacy of TJ-68 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
Conditions
Interventions
TJ-68
Placebo
Locations
3
United States
Mayo Clinic
Scottsdale, Arizona, United States
Mayo Clinic
Jacksonville, Florida, United States
Columbia University Irving Medical Center
New York, New York, United States
Start Date
September 30, 2022
Primary Completion Date
July 26, 2024
Completion Date
July 26, 2024
Last Updated
May 1, 2025
NCT07322003
NCT07414212
NCT05104710
NCT03233646
NCT04715399
NCT07357428
Lead Sponsor
Hiroshi Mitsumoto
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions